Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLISS: Anti-PD1 Protocol in NSCLC in Brazil
NCT05081674Phase 2Completed
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Jan 2020
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and nivolumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Hospital Israelita Albert Einstein. Primary endpoint: Total cost of therapy at 3 years. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05081674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05081674.